Table 4.
Characteristic Differences and Endpoint Distributions Among 17,171 Antiretroviral Therapy Initiators in the North American AIDS Cohort Collaboration on Research and Design, By Injection Drug Use as HIV Risk Factor, 2000–2010
| Characteristica | IDU | Non-IDU | p |
|---|---|---|---|
| Total | 3212 (19) | 13,959 (81) | |
| Time in follow-up (years) | 3.85 (1.8, 6.1) | 3.99 (1.9, 6.2) | 0.30 |
| Age (years) | 50 (44, 55) | 46 (39, 55) | <0.001 |
| Sex | 0.66 | ||
| Male | 2680 (19) | 11,691 (81) | |
| Female | 532 (19) | 2268 (81) | |
| Race | <0.001 | ||
| Nonblack | 1378 (14) | 8228 (86) | |
| Black | 1834 (24) | 5731 (76) | |
| CD4+ countb (cells/mm3) | 266 (106, 455) | 251 (84, 430) | <0.001 |
| Nadir CD4+ countc (cells/mm3) | 160 (48, 281) | 163 (42, 290) | 0.65 |
| HIV-1 RNAd (log10 copies/mL) | 4.418 (3.28, 5.05) | 4.547 (3.30, 5.17) | <0.001 |
| Event | N | Years in FU | N | Years in FU | p |
|---|---|---|---|---|---|
| Death | 340 | 3.16 (1.81, 4.86) | 1171 | 2.66 (1.47, 4.45) | 0.001 |
| Discontinuity in care | 1623 | 2.37 (1.40, 4.20) | 6744 | 2.46 (1.42, 4.21) | 0.48 |
| Event free | 1249 | 5.91 (4.24, 7.99) | 6044 | 5.81 (4.25, 7.88) | 0.26 |
p-Value calculated by χ2 for categorical variables, Kruskal–Wallis for continuous variables.
a
Numbers presented as N (%) if categorical, as median (IQR) if continuous.
b
At ART initiation, available for N = 14,356 individuals.
c
After ART initiation, available for N = 17,171 individuals.
d
At ART initiation, available for N = 14,261 individuals.
ART, antiretroviral therapy; FU, follow-up; IDU, injection drug use; IQR, interquartile range.